On 30 Sep 2019, BeyondSpring Inc. (NASDAQ: BYSI) changed 5.91% to recent value of $18.1. The stock transacted 29505 shares during most recent day however it has an average volume of 72.47K shares. It spotted trading -30.65% off 52-week high price. On the other end, the stock has been noted 38.59% away from the low price over the last 52-weeks.
BeyondSpring Inc. (BYSI) recently reported that the Company’s novel trial design for DUBLIN-3 (Study BPI-2358-103) for its lead asset and first-in-class agent, Plinabulin, was selected for poster presentation at this year’s European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain. The poster, titled, “DUBLIN-3, a Stage IIIb/IV NSCLC Phase (Ph)3 Trial Comparing the Plinabulin (P)/Docetaxel(D) Combination with D Alone,” was presented on September 28.
“When going up against Docetaxel – an established, highly effective treatment for second- and third-line NSCLC – for a comparison trial, Avelumab may have failed Because of critical trial design considerations, which were avoided with the design of DUBLIN-3,” stated Dr. Ramon Mohanlal, BeyondSpring’s Executive Vice President, R&D, and Chief Medical Officer. “With PD-1 inhibitor therapy (in combination with platinum/pemetrexed) moving into first-line NSCLC, PD-1/PD-L1 inhibitors are no longer an option in second- and third-line for patients who became resistant to them in first-line treatment. Therefore, Docetaxel is the standard of care for second- and third-line NSCLC. If the Plinabulin/Docetaxel combination meets its intended target product profile of superior survival benefit, superior safety and QoL contrast to Docetaxel alone, it has the potential to become the preferred second- and third-line treatment option in NSCLC. Based on the first pre-planned interim analysis with DUBLIN-3 in Q1 2019, the study could continue without modifications, as concluded by the DSMB. The second interim analysis is projected for Q1 2020, after which the trial could be stopped, if pre-specified statistics are met.”
Its earnings per share (EPS) expected to touch remained 45.00% for this year. The company has 26.01M of outstanding shares and 8.02M shares were floated in the market. According to the most recent quarter its current ratio was 0.1 that represents company’s ability to meet its current financial obligations. The price moved ahead of -2.60% from the mean of 20 days, 4.45% from mean of 50 days SMA and performed 1.72% from mean of 200 days price. Company’s performance for the week was 1.51%, 2.72% for month and YTD performance remained -3.47%.